Dose intensification of vedolizumab is not effective in inducing endoscopic response in Crohn's disease patients with endoscopic primary non-response

被引：0
|
作者：
Oldenburg, L.
Baert, F.
Bossuyt, P.
Hoentjen, F.
Clasquin, E.
Molnar, T.
Loewenberg, M.
Vermeire, S.
D'Haens, G.
机构：
[1] Univ Amsterdam, Med Ctr, Gastroenterol, Amsterdam, Netherlands
[2] AZ Delta, Gastroenterol, Roeselare, Belgium
[3] Imelda Gen Hosp, Gastroenterol, Bonheiden, Belgium
[4] Univ Alberta, Gastroenterol, Edmonton, AB, Canada
[5] Univ Szeged, Internal Med, Szeged, Hungary
[6] Univ Hosp Leuven, Gastroenterol, Leuven, Belgium
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.0009
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OP09
引用
收藏
页码：i17 / i18
页数：2
相关论文
共 50 条
  • [41] Symptomatic luminal stricture underlies infliximab non-response in Crohn's disease (CD)
    Prajapati, DN
    Saeian, K
    Kim, JP
    Kugathasan, S
    Knox, JF
    Emmons, J
    Binion, DG
    GASTROENTEROLOGY, 2002, 122 (04) : A100 - A100
  • [42] Is endoscopic treatment of small bowel strictures effective and safe in patients with Crohn's disease?
    Valdes del Pino, Yacqueline
    Giordano, Antonio
    Escapa, Miriam
    Ricart, Elena
    Ordas, Ingrid
    Rodriguez, Sonia
    Rimola, Jordi
    Fernandez-Esparrach, Gloria
    Gines, Angels
    Llach, Josep
    Panes, Julia
    Gonzalez-Suarez, Begona
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2020, 112 (04) : 284 - 289
  • [43] Higher clinical remission and endoscopic response with vedolizumab in early versus late Crohn's disease: data from the LOVE-CD trial
    Oldenburg, L.
    Baert, F.
    Bossuyt, P.
    Hoentjen, F.
    Clasquin, E.
    Molnar, T.
    Loewenberg, M.
    Vermeire, S.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i238 - i239
  • [44] Multi-alleles predict primary non-response to infliximab therapies in Crohn's disease: a simple and practicable model
    Tang, J.
    Zhang, C.
    Wang, X.
    Gao, X.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S190 - S191
  • [45] Studies show rapid clinical and endoscopic Response with Upadacitinib and Risankizumab in Crohn's Disease
    不详
    VISCERAL MEDICINE, 2024, 40 (03)
  • [46] Early change in faecal calprotectin predicts primary non-response to anti-TNF therapy in Crohn's disease
    Pavlidis, Polychronis
    Gulati, Shraddha
    Dubois, Patrick
    Chung-Faye, Guy
    Sherwood, Roy
    Bjarnason, Ingvar
    Hayee, Bu'Hussain
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (12) : 1447 - 1452
  • [47] Intravenous, Weight-Based Tumor Necrosis Factor (TNF) Antagonists Are Effective in the Treatment of Patients With Moderate to Severe Crohn's Disease With Prior Primary Non-response to Subcutaneous, Fixed-Dose TNF
    Clark-Snustad, Kindra
    Singla, Anand
    Park, Christopher
    Dumais, Mitchell
    Lee, Scott D.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S399 - S400
  • [48] Rates of Clinical Response, Clinical Remission and Endoscopic Response in Crohn's Disease: Monotherapy Versus Combined Therapy
    Bruna, Moutinho
    Julio, Baima
    Rogerio, Saad-Hossne
    Ligia, Sassaki
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S19 - S19
  • [49] Microbial signature of the colon is not associated with response to vedolizumab in Crohn's disease
    Hageman, I.
    Joustra, V.
    Yim, A. Li
    Davids, M.
    Henneman, P.
    Hakvoort, T.
    Probert, F.
    Satsangi, J.
    D'Haens, G.
    De Jonge, W.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I603 - I604
  • [50] Microbial signature of the colon is not associated with response to vedolizumab in Crohn's disease
    Hageman, I.
    Joustra, V.
    Li Yim, A.
    Davids, M.
    Henneman, P.
    Hakvoort, T.
    Probert, F.
    Satsangi, J.
    D'Haens, G.
    De Jonge, W.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I603 - I604
12345